Method update: Myeloproliferative neoplasm referrals, confirmation testing
Our Cambridge Lab have updated their methods to streamline and standardise processes for confirmation testing of variants identified from standalone assay testing for CALR (NGTD (opens in a new tab) code M85.16), JAK2 (exon 12) (M85.15) and MPL (exon 10) (M85.17) for myeloproliferative neoplasm. Confirmation tests will now be performed via next-generation sequencing, in place of Sanger sequencing.
No action is required by referring clinicians.